Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Summit begins dosing in Phase III trials of ridinilazole

Ridinilazole is an oral small molecule designed to selectively destroy C. difficile bacteria. Credit: AJC1.



  • Summit begins dosing in Phase III trials of ridinilazole

Go Top